REVIEW

Recent advances in the epidemiology, diagnosis, and management of *Trichomonas vaginalis* infection [version 1; peer review: 2 approved]

Olivia T. Van Gerwen , Christina A. Muzny

Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, 35294, USA

V1 First published: 20 Sep 2019, 8(F1000 Faculty Rev):1666
<https://doi.org/10.12688/f1000research.19972.1>

Latest published: 20 Sep 2019, 8(F1000 Faculty Rev):1666
<https://doi.org/10.12688/f1000research.19972.1>

Abstract

Trichomonas vaginalis is the most common, curable non-viral sexually transmitted infection (STI) worldwide. Despite this burden of disease, it is not currently a reportable disease in the United States. Recent advances in the epidemiology, diagnosis, and management of *T. vaginalis* infection are described in this article. This includes updated global and U.S. prevalence data in women and men as well as recent epidemiological data in HIV-infected individuals and pregnant women. Advances in molecular diagnostics are also reviewed, as are data from recent clinical trials regarding the treatment of trichomonas in women.

Keywords

Trichomonas vaginalis, vaginal infections, STI

Open Peer Review

Approval Status

	1	2
version 1		
20 Sep 2019		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Jack Sobel**, Wayne State University School of Medicine, Detroit, USA
2. **Paul Nyirjesy**, Drexel University College of Medicine, Philadelphia, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Christina A. Muzny (cmuzny@uabmc.edu)

Author roles: Van Gerwen OT: Resources, Writing – Original Draft Preparation, Writing – Review & Editing; Muzny CA: Conceptualization, Supervision, Writing – Review & Editing

Competing interests: Christina A. Muzny is a consultant for Lupin Pharmaceuticals, BioFire Diagnostics, and Cepheid. She has also received honoraria from Roche Diagnostics and Becton Dickinson. Olivia T. Van Gerwen declares that she has no competing interests.

Grant information: Olivia T. Van Gerwen is currently supported by grant T32 HS013852 from the Agency for Healthcare Research and Quality. Christina A. Muzny is currently supported by the National Institute of Allergy and Infectious Diseases (grant K23AI106957-01A1). *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

Copyright: © 2019 Van Gerwen OT and Muzny CA. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Van Gerwen OT and Muzny CA. **Recent advances in the epidemiology, diagnosis, and management of *Trichomonas vaginalis* infection [version 1; peer review: 2 approved]** F1000Research 2019, 8(F1000 Faculty Rev):1666 <https://doi.org/10.12688/f1000research.19972.1>

First published: 20 Sep 2019, 8(F1000 Faculty Rev):1666 <https://doi.org/10.12688/f1000research.19972.1>

Introduction

Trichomonas vaginalis is the most common, non-viral sexually transmitted infection (STI) worldwide¹. Patients with symptomatic *T. vaginalis* report various symptoms, including vaginal discharge and dysuria in women and urethral discharge and dysuria in men^{2–4}. Many infected patients, however, never experience symptoms³. Untreated or persistent *T. vaginalis* in women has been associated with infertility and adverse birth outcomes^{5–7}. While less is known about *T. vaginalis* in men, it has been described as a cause of nongonococcal urethritis (NGU), prostatitis, and epididymitis⁴. *T. vaginalis* has also been linked to an increased risk of HIV, posing a major public health threat⁸. Nevertheless, *T. vaginalis* remains understudied given the lack of public health attention it has received⁹. It is not currently a reportable disease in the U.S., as it has previously been found to meet only three out of seven criteria¹⁰. This review aims to provide an update on recent advances in the epidemiology, diagnosis, and treatment of *T. vaginalis*.

Epidemiology

The World Health Organization (WHO) estimated 156 million cases of *T. vaginalis* worldwide in 2016, accounting for almost half of the global STI incidence that year¹. Updated epidemiological data on the national prevalence of trichomonas among women and men in the U.S. was published in 2018¹¹. These data were collected during 2013–2014 in the National Health and Nutrition Examination Survey (NHANES) using the Hologic Gen-Probe Aptima® *T. vaginalis* assay on urine specimens. *T. vaginalis* prevalence was 1.8% in women and 0.5% in men aged 18–59 years. Prior to this study, the national prevalence of *T. vaginalis* had been poorly characterized among U.S. men as a result of diagnostic challenges; NHANES did not test men for *T. vaginalis* until 2013–2014. Spontaneous resolution of *T. vaginalis* is known to occur at relatively high rates (36–69%) in men^{12,13}, which may explain the lower prevalence compared to women in the recent NHANES study. While *T. vaginalis* is less common in men¹¹, it is readily passed between sexual partners during penile–vaginal sex, even when the infected partner is asymptomatic. Thus, treatment of infected men is an important public health concern¹⁴. In men who have sex with men (MSM), *T. vaginalis* rarely causes urethral or rectal infection, and screening in asymptomatic individuals is of low utility¹⁵.

A marked racial disparity regarding *T. vaginalis* was noted among African American women and men in the recent NHANES study, with an estimated prevalence of 6.8% among the black population compared to 0.4% among other groups¹¹. This is consistent with 2001–2004 NHANES data which found higher rates of *T. vaginalis* in African American women compared to women of other races/ethnicities¹⁶. This pronounced racial disparity is likely multifactorial, involving differences in sexual networks, individual-level sexual risk behaviors such as larger numbers of sexual partners, and structural disparities (i.e. inadequate access to healthcare resources)^{17–19}.

In the recent NHANES study, *T. vaginalis* was found to be significantly associated with older age, lower educational level,

lower socioeconomic status, and having two or more sexual partners in the past year¹¹. Compared to other high-income countries such as the United Kingdom, *T. vaginalis* prevalence in the U.S. is higher, possibly a function of the lack of public health consideration it receives²⁰.

The only population for which routine *T. vaginalis* screening is currently recommended in the U.S. is HIV-infected women²¹. Even in the absence of symptoms, *T. vaginalis* in this population has been associated with high rates of adverse events such as pelvic inflammatory disease (PID) and poor birth outcomes^{5,22}. Several recent studies have found high *T. vaginalis* prevalence (17.4–20%)^{23–26} and repeat infection rates (up to 22.7% over a median of 16 months) among HIV-infected women²³. Similar to HIV-uninfected men, *T. vaginalis* is less common in HIV-infected men and infrequently seen in HIV-infected MSM²⁴.

Since *T. vaginalis* has been associated with adverse birth outcomes, its effect on pregnant women is important to consider⁶. Currently, there are no recommendations for screening of asymptomatic pregnant women for *T. vaginalis*. This is largely owing to results from a prior randomized controlled trial (RCT) of asymptomatic pregnant women with *T. vaginalis*²⁷. This study found a higher risk of preterm delivery among women treated with two doses (2 grams each) of metronidazole (MTZ) 48 hours apart between 16 and 23 and between 24 and 29 weeks of gestation, respectively, versus placebo. However, this trial had several limitations including atypical MTZ dosing. In addition, the second round of MTZ was given between 24 and 29 weeks' gestation, whereas the greatest increase of pre-term delivery was at 35–36 weeks in this study. Because of this, definitive conclusions regarding an association between MTZ treatment of asymptomatic *T. vaginalis* during pregnancy and pre-term birth cannot be made and further studies are needed^{27,28}.

The global prevalence of *T. vaginalis* in pregnant women varies geographically. A 2016 systematic review of 75 studies of STI prevalence among pregnant women found that *T. vaginalis* prevalence ranged from 3.9–24.6% in low- to middle-income countries (i.e. Latin America and Southern Africa)²⁹. Recent studies found a *T. vaginalis* prevalence of 20% among HIV-infected pregnant women in South Africa²⁶ as well as high rates of incident infection in pregnant women (9.2/100 person-years) in South Africa and Zimbabwe³⁰. Unexpectedly high rates of persistent *T. vaginalis* (44% at 21 days or more following treatment) by nucleic acid amplification test (NAAT) in pregnant women in the Southern U.S. have been noted by Lazenby *et al.*³¹. This is higher than the rate of 7% in pregnant women noted in a previous U.S. study²⁷. Based on their data, Lazenby *et al.* suggested that all pregnant women with *T. vaginalis* should be re-tested with NAATs approximately 3 weeks post-treatment³¹.

Diagnosis

The primary diagnostic modality for *T. vaginalis* has traditionally been microscopic examination of a wet mount of vaginal

fluid, looking for motile trichomonads³². While wet mount is inexpensive and rapid, its use is limited by low sensitivity, which ranges from 44–68% compared to culture³³. Prior to the advent of NAATs, culture was the gold standard for diagnosis of *T. vaginalis*, with a sensitivity of 81–94%^{34–36}. Diamond's medium is the traditional culture method used for the isolation of *T. vaginalis*³⁷. However, contamination with vaginal bacteria is common, making this technique difficult³⁴. Culture systems, such as the InPouch® system (BioMed Diagnostics, White City, OR), have been developed to avoid contamination by placing the specimen in a two-chambered bag, allowing for simultaneous sampling for wet mount and culture while maintaining similar efficacy to Diamond's medium³⁸.

Despite relatively high sensitivity and specificity, *T. vaginalis* culture remains time consuming, as it requires incubation and reading of the InPouch® over several days³⁹. It is categorized by the Clinical Laboratory Improvement Amendments (CLIA) as moderately complex⁴⁰. Over the past several years, molecular testing for *T. vaginalis* has become the preferred diagnostic modality²¹. There are three US Food and Drug Administration (FDA)-approved *T. vaginalis* NAATs currently available in the U.S., all of which are able to detect co-infection with gonorrhea and chlamydia from the same specimen^{33,41–43}. The Aptima® *T. vaginalis* assay (Hologic, Bedford, MA) was the first NAAT to be approved by the FDA for *T. vaginalis* detection in asymptomatic and symptomatic women⁴¹. This assay detects an rRNA target via transcription-mediated amplification (TMA), with sensitivity ranging from 88–100% and specificity from 98–100%⁴⁴. It can be performed on clinician-obtained vaginal and endocervical swab specimens, urine specimens, and ThinPrep PreservCyt specimens with results in less than 8 hours⁴¹. Importantly, it has not been FDA approved for use in men and must be internally validated before use³³. The BD ProBTec *T. vaginalis* Q^x (TVQ) amplified DNA assay (BD Diagnostics, Baltimore, MD) was the second *T. vaginalis* NAAT approved by the FDA for use in female urine, endocervical swab specimens, and patient- or clinician-obtained vaginal specimens⁴². Similar to the Aptima® TV assay, this test is only FDA approved in women and must be internally validated prior to use in men. The TVQ assay is able to yield results in less than 8 hours⁴².

The Xpert® TV assay (Cepheid, Sunnyvale, CA) was the first *T. vaginalis* NAAT FDA approved for use in female urine, endocervical swab, and patient- and clinician-collected vaginal specimens as well as male urine⁴³. Diagnostic sensitivity and specificity for the Xpert® TV assay range from 99.5–100% and 99.4–99.9% for female genital specimens and 97.2–99.9% for male urine specimens⁴³. Once collected and placed in the testing platform, the Xpert® TV assay yields results in 60–90 minutes, allowing for point-of-care (POC) diagnosis and management⁴⁵.

POC STI diagnostics are powerful tools, allowing providers to accurately diagnose and provide appropriate treatment for patients in the same visit. Given the communicability and frequency of *T. vaginalis*, rapid diagnosis and treatment could

have a substantial impact on its public health burden⁴⁶. The Solana® Trichomonas assay (Quidel, San Diego, CA) is a new rapid test for the qualitative detection of *T. vaginalis* DNA and can yield results within 40 minutes of specimen collection⁴⁷. This assay was FDA approved in 2017 for the diagnosis of *T. vaginalis* from female vaginal and urine specimens from asymptomatic and symptomatic women, with sensitivity compared to NAAT of over 98% for vaginal specimens and over 92% for urine⁴⁷. Solana® requires a specific testing instrument to process samples; thus, similar to NAATs, there is upfront cost associated with its use. After a specimen is collected, it is lysed by heat, diluted, and added to a reaction tube containing helicase-dependent amplification (HDA) reagents including primers specific for the amplification of a *T. vaginalis*-specific target sequence (<https://www.quidel.com/molecular-diagnostics/solana-trichomonas-assay>). The AmpliVue® Trichomonas Assay (Quidel, San Diego, CA) is another POC test providing qualitative detection of *T. vaginalis* which is FDA approved for vaginal specimens from symptomatic and asymptomatic women⁴⁸. Similar to Solana®, AmpliVue® also uses HDA technology but testing can be performed in a small handheld cartridge that requires no additional equipment (<http://www.quidel.com/molecular-diagnostics/amplivue-products>). AmpliVue® has demonstrated comparable sensitivity and specificity to the Aptima® TV assay, at 90.7% and 98.9%, respectively⁴⁸.

The OSOM® Trichomonas Rapid Test (Sekisui, Framingham, MA) is a qualitative antigen-detection immunochromatographic assay with a processing time of 10–15 minutes⁴⁹. It is validated for the diagnosis of *T. vaginalis* in women from clinician-obtained vaginal specimens with a sensitivity of 83–92% and specificity of 99%^{50,51}. This test has not performed well in identifying infection in male urine when compared to the Aptima® TV assay⁵¹; thus, it is currently recommended in women only²¹. Because it requires no special equipment and is low cost, the OSOM® test is appealing in the setting of STI testing campaigns in low-resource settings⁵².

With the advent of these numerous high-quality *T. vaginalis* diagnostics, clinicians should be aware of which of the above tests are currently available in their laboratories beyond wet mount. In choosing which of the above diagnostic tests to use, the need for a rapid diagnosis should be balanced with the need for a highly sensitive test. Furthermore, there are several additional trichomoniasis diagnostic tests in the pipeline whose performance characteristics have not yet been published.

Management

The management of trichomoniasis continues to evolve, particularly in women. Per the 2015 Centers for Disease Control and Prevention (CDC) sexually transmitted disease treatment guidelines²¹, first-line treatment for trichomoniasis in HIV-negative women and men includes a single 2 gram dose of oral MTZ or tinidazole (TIN). Oral MTZ 500 mg twice daily for 7 days is an alternative therapy. These recommendations were based on several small trials conducted over 30 years ago^{53–56}, several of which had a high potential for bias, as well as a desire to

reduce adherence issues with multi-dose therapy. A meta-analysis of prior trichomonas treatment trials recently showed that women receiving the 7-day regimen of oral MTZ were 50% less likely to be positive at test of cure (TOC) compared to those receiving single-dose therapy⁵⁷. In addition, RCTs of HIV-infected women with *T. vaginalis*⁵⁸ and HIV-negative women with *T. vaginalis*⁵⁹ found that the 7-day MTZ dose was more effective than single-dose therapy at TOC. While the CDC recommends only 7-day MTZ for HIV-infected women, it is highly likely that this regimen will be recommended for all women moving forward⁶⁰. Of note, a recent literature review found no increased risk of teratogenicity with the use of MTZ (a class B drug) during pregnancy⁶¹. TIN has not been evaluated in pregnancy and remains a class C drug.

There have been no head-to-head comparisons of the single 2 gram dose of oral MTZ and the 7-day regimen in men. One observational study of 325 men with trichomoniasis found that treatment with the 2 gram dose of oral MTZ was unsuccessful in 42.9% of cases⁶². A second study found that the microbiological efficacy of treatment with the 2 gram dose of oral MTZ in men was 77.1%⁶³. While these cure rates seem to be suboptimal, neither of these studies had a comparison group with the 7-day MTZ regimen; thus, no conclusions can be made.

In addition to MTZ, TIN is another 5-nitroimidazole medication that is FDA approved and recommended by the CDC for the treatment of trichomoniasis. TIN has better absorption and fewer gastrointestinal side effects than MTZ⁶⁴ but is ten times more expensive (with an approximate retail price of \$44.66 per 2 gram dose, compared with \$3.47 per 2 gram dose of MTZ at the time of writing)³ and less likely to be adopted by clinicians. Other nitroimidazoles, such as secnidazole⁶⁵ and ornidazole^{63,66}, have been used in other countries but are not currently FDA approved for the treatment of trichomoniasis in the U.S.

Persistent or recurrent infection due to antimicrobial-resistant *T. vaginalis* or other causes should be differentiated from reinfection from an untreated or insufficiently treated sexual partner. A detailed patient history should be taken to assess the likelihood of reinfection. Following treatment failure, and if reinfection has been excluded, persistent or recurrent trichomoniasis³ has been treated successfully with longer courses or additional doses of the same medications used in standard therapy (i.e. high-dose oral MTZ or TIN 2 grams orally daily for 7 days)²¹. Single-dose MTZ or TIN therapy should be avoided²¹. If drug resistance is suspected, the isolate can also be sent to the CDC for drug resistance testing (https://www.cdc.gov/laboratory/specimen-submission/detail.html?CDC_TestCode=CDC-10239). If the patient fails the 7-day regimen of high-dose oral MTZ or TIN, two additional treatment options are available which have had successful results. The first is high-dose oral TIN 2–3 grams daily (in divided doses) plus intravaginal TIN 500 mg twice daily for 14 days⁶⁷. The second is high-dose oral TIN (1 gram three times daily) plus intravaginal paromomycin (4 g of 6.25% intravaginal paromomycin cream nightly) for 14 days^{68,69}. Paromomycin is an aminoglycoside

with a different mechanism of action (destruction of ribosomal RNA) than MTZ (inhibition of nucleic acid synthesis by DNA disruption)⁷⁰; successful treatment of MTZ-resistant trichomoniasis with both high-dose oral TIN and intravaginal paromomycin may suggest a synergistic effect. It should be noted, however, that intravaginal paromomycin cream may cause vaginal ulceration(s)⁷¹. These ulcerations may spontaneously regress when therapy is stopped. Expert consultation should be sought for additional treatment options for patients who fail the above treatment options. There are currently no data regarding optimal treatment of male sexual partners of women with MTZ-resistant trichomoniasis.

Another complicated treatment scenario for women with trichomoniasis is the setting of an IgE-mediated-type hypersensitivity reaction to 5-nitroimidazoles. These patients should be managed by MTZ desensitization according to a published regimen^{72,73} and in consultation with an allergy specialist²¹. Treatment of patients with *T. vaginalis* who are unable to be desensitized is difficult and mainly based on anecdotal data^{21,74}. One option for which we have had success is intravaginal boric acid 600 mg twice daily for 60 days^{75,76}.

Partner treatment

Per current CDC sexually transmitted disease treatment guidelines, concurrent treatment of all sexual partners of patients with trichomoniasis is critical for symptomatic relief, microbiologic cure, and prevention of transmission and reinfection²¹. In the last several years, the evidence for expedited partner therapy (EPT) as a mechanism of prevention of *T. vaginalis* infection has grown⁷⁷. EPT, or the treatment of sexual partners of a patient diagnosed with an STI by providing treatment prescriptions to the patient without clinical assessment of the partners⁷⁸, has been recognized as an effective option for partner treatment of chlamydia and gonorrhea⁷⁹. The CDC currently recommends EPT as an option for partner therapy for these STIs in women and heterosexual men^{21,79}. Interestingly, two prior RCTs conducted on the use of EPT in partners of women with trichomoniasis had mixed results^{80,81}. Schwebke *et al.* found EPT to be well accepted and safe with rates of repeat infection in the EPT arm lower than those of the public health disease intervention and partner-referral arms⁸¹. In an RCT by Kissinger *et al.*, however, randomization to *T. vaginalis* EPT did not lead to increased partner treatment uptake or lower follow-up rates compared to standard partner referral⁸⁰. Nevertheless, given high reinfection rates and frequent asymptomatic infection in men, EPT is still recommended as a valid means of partner therapy of *T. vaginalis*-infected patients²¹. EPT has also recently been shown to be effective in decreasing repeat *T. vaginalis* infection rates when used in conjunction with POC testing strategies in South African women⁵². Despite some data supporting EPT for patients with *T. vaginalis*, implementation has been limited because of legal restrictions in many states (<https://www.cdc.gov/std/ept/legal/default.htm>). Additionally, EPT acceptance has been found to vary with patient and provider characteristics⁸². It is currently unknown how often providers prescribe EPT for trichomoniasis in the U.S.

Conclusion

In recent years, many advances have been made in the epidemiology, diagnosis, and treatment of *T. vaginalis*. The focus of these efforts, however, has largely been on women.

More study is needed on the epidemiology of trichomoniasis in men as well as how to best diagnose and treat men who are infected, particularly given its high prevalence and communicability.

References

1. **F** Rowley J, Vander Hoorn S, Korenromp E, *et al.*: Chlamydia, gonorrhoea, trichomoniasis and syphilis: Global prevalence and incidence estimates, 2016. *Bull World Health Organ.* 2019; **97**(8): 548–562P.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
2. ACOG Committee on Practice Bulletins–Gynecology: ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists, Number 72, May 2006: Vaginitis. *Obstet Gynecol.* 2006; **107**(5): 1195–206.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Meites E, Gaydos CA, Hobbs MM, *et al.*: A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic *Trichomonas vaginalis* Infections. *Clin Infect Dis.* 2015; **61**(Suppl 8): S837–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Krieger JN: Trichomoniasis in men: Old issues and new data. *Sex Transm Dis.* 1995; **22**(2): 83–96.
[PubMed Abstract](#)
5. Cotch MF, Pastorek JG 2nd, Nugent RP, *et al.*: *Trichomonas vaginalis* associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. *Sex Transm Dis.* 1997; **24**(6): 353–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Silver BJ, Guy RJ, Kaldor JM, *et al.*: *Trichomonas vaginalis* as a cause of perinatal morbidity: A systematic review and meta-analysis. *Sex Transm Dis.* 2014; **41**(6): 369–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Mielczarek E, Blaszkowska J: *Trichomonas vaginalis*: Pathogenicity and potential role in human reproductive failure. *Infection.* 2016; **44**(4): 447–58.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. **F** McClelland RS, Sangare L, Hassan WM, *et al.*: Infection with *Trichomonas vaginalis* increases the risk of HIV-1 acquisition. *J Infect Dis.* 2007; **195**(5): 698–702.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
9. Muzny CA: Why Does *Trichomonas vaginalis* Continue to be a “Neglected” Sexually Transmitted Infection? *Clin Infect Dis.* 2018; **67**(2): 218–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Hoots BE, Peterman TA, Torrone EA, *et al.*: A Trich-y question: Should *Trichomonas vaginalis* infection be reportable? *Sex Transm Dis.* 2013; **40**(2): 113–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. **F** Patel EU, Gaydos CA, Packman ZR, *et al.*: Prevalence and Correlates of *Trichomonas vaginalis* Infection Among Men and Women in the United States. *Clin Infect Dis.* 2018; **67**(2): 211–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
12. Krieger JN, Verdon M, Siegel N, *et al.*: Natural history of urogenital trichomoniasis in men. *J Urol.* 1993; **149**(6): 1455–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. **F** Schwebke JR, Rompalo A, Taylor S, *et al.*: Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens—a randomized clinical trial. *Clin Infect Dis.* 2011; **52**(2): 163–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
14. Seña AC, Miller WC, Hobbs MM, *et al.*: *Trichomonas vaginalis* infection in male sexual partners: implications for diagnosis, treatment, and prevention. *Clin Infect Dis.* 2007; **44**(1): 13–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Kelley CF, Rosenberg ES, O'Hara BM, *et al.*: Prevalence of urethral *Trichomonas vaginalis* in black and white men who have sex with men. *Sex Transm Dis.* 2012; **39**(9): 739.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Sutton M, Sternberg M, Koumans EH, *et al.*: The prevalence of *Trichomonas vaginalis* infection among reproductive-age women in the United States, 2001–2004. *Clin Infect Dis.* 2007; **45**(10): 1319–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Ford JL, Browning CR: Neighborhood social disorganization and the acquisition of trichomoniasis among young adults in the United States. *Am J Public Health.* 2011; **101**(9): 1696–703.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Kraut-Becher J, Eisenberg M, Voytek C, *et al.*: Examining racial disparities in HIV: lessons from sexually transmitted infections research. *J Acquir Immune Defic Syndr.* 2008; **47** Suppl 1: S20–7.
[PubMed Abstract](#)
19. Sorvillo F, Smith L, Kerndt P, *et al.*: *Trichomonas vaginalis*, HIV, and African-Americans. *Emerg Infect Dis.* 2001; **7**(6): 927–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Field N, Clifton S, Alexander S, *et al.*: *Trichomonas vaginalis* infection is uncommon in the British general population: implications for clinical testing and public health screening. *Sex Transm Infect.* 2018; **94**(3): 226–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Workowski KA, Bolan GA, Centers for Disease Control and Prevention: Sexually transmitted diseases treatment guidelines, 2015. *MMWR Recomm Rep.* 2015; **64**(RR-03): 1–137.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Moodley P, Wilkinson D, Connolly C, *et al.*: *Trichomonas vaginalis* is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. *Clin Infect Dis.* 2002; **34**(4): 519–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Muzny CA, Tamhane AR, Eaton EF, *et al.*: Incidence and predictors of reinfection with trichomoniasis based on nucleic acid amplification testing results in HIV-infected patients. *Int J STD AIDS.* 2019; **30**(4): 344–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Muzny CA, Burkholder GA, Fry KR, *et al.*: *Trichomonas vaginalis* Nucleic Acid Amplification Testing at an Urban HIV Clinic. *Sex Transm Dis.* 2016; **43**(8): 483–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Sorvillo F, Kovacs A, Kerndt P, *et al.*: Risk factors for trichomoniasis among women with human immunodeficiency virus (HIV) infection at a public clinic in Los Angeles County, California: implications for HIV prevention. *Am J Trop Med Hyg.* 1998; **58**(4): 495–500.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. **F** Price CM, Peters RPH, Steyn J, *et al.*: Prevalence and Detection of *Trichomonas vaginalis* in HIV-Infected Pregnant Women. *Sex Transm Dis.* 2018; **45**(5): 332–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
27. **F** Klebanoff MA, Carey JC, Hauth JC, *et al.*: Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic *Trichomonas vaginalis* infection. *N Engl J Med.* 2001; **345**(7): 487–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
28. Coleman JS, Gaydos CA, Witter F: *Trichomonas vaginalis* vaginitis in obstetrics and gynecology practice: new concepts and controversies. *Obstet Gynecol Surv.* 2013; **68**(1): 43–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Joseph Davey DL, Shull HI, Billings JD, *et al.*: Prevalence of Curable Sexually Transmitted Infections in Pregnant Women in Low- and Middle-Income Countries From 2010 to 2015: A Systematic Review. *Sex Transm Dis.* 2016; **43**(7): 450–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. **F** Teasdale CA, Abrams EJ, Chiasson MA, *et al.*: Incidence of sexually transmitted infections during pregnancy. *PLoS One.* 2018; **13**(5): e0197696.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
31. **F** Lazenby GB, Thompson L, Powell AM, *et al.*: Unexpected High Rates of Persistent *Trichomonas vaginalis* Infection in a Retrospective Cohort of Treated Pregnant Women. *Sex Transm Dis.* 2019; **46**(1): 2–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
32. Schwebke JR, Burgess D: Trichomoniasis. *Clin Microbiol Rev.* 2004; **17**(4): 794–803, table of contents.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Hobbs MM, Seña AC: Modern diagnosis of *Trichomonas vaginalis* infection. *Sex Transm Infect.* 2013; **89**(6): 434–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Garber GE: The laboratory diagnosis of *Trichomonas vaginalis*. *Can J Infect Dis Med Microbiol.* 2005; **16**(1): 35–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Beverly AL, Venglarik M, Cotton B, *et al.*: Viability of *Trichomonas vaginalis* in

- transport medium. *J Clin Microbiol*. 1999; 37(11): 3749–50.
[PubMed Abstract](#) | [Free Full Text](#)
36. Ohlemeyer CL, Hornberger LL, Lynch DA, *et al.*: **Diagnosis of *Trichomonas vaginalis* in adolescent females: InPouch TV culture versus wet-mount microscopy.** *J Adolesc Health*. 1998; 22(3): 205–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Garber GE, Sibau L, Ma R, *et al.*: **Cell culture compared with broth for detection of *Trichomonas vaginalis*.** *J Clin Microbiol*. 1987; 25(7): 1275–9.
[PubMed Abstract](#) | [Free Full Text](#)
 38. Beal C, Goldsmith R, Kotby M, *et al.*: **The plastic envelope method, a simplified technique for culture diagnosis of trichomoniasis.** *J Clin Microbiol*. 1992; 30(9): 2265–8.
[PubMed Abstract](#) | [Free Full Text](#)
 39. Rivers CA, Muzny CA, Schwabke JR: **Diagnostic rates differ on the basis of the number of read days with the use of the InPouch culture system for *Trichomonas vaginalis* screening.** *J Clin Microbiol*. 2013; 51(11): 3875–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 40. Hobbs MM SA, Swygard H, *et al.*: ***Trichomonas vaginalis* and trichomoniasis.** In: Holmes KK SP, Stamm WE, *et al.* ed. Sexually Transmitted Diseases. 4th ed. New York: McGraw-Hill; 2008: 771–93.
 41. Schwabke JR, Hobbs MM, Taylor SN, *et al.*: **Molecular testing for *Trichomonas vaginalis* in women: results from a prospective U.S. clinical trial.** *J Clin Microbiol*. 2011; 49(12): 4106–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 42. van der Pol B, Williams JA, Taylor SN, *et al.*: **Detection of *Trichomonas vaginalis* DNA by use of self-obtained vaginal swabs with the BD ProbeTec Q² assay on the BD Viper system.** *J Clin Microbiol*. 2014; 52(3): 885–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 43. **F** Schwabke JR, Gaydos CA, Davis T, *et al.*: **Clinical Evaluation of the Cepheid Xpert TV Assay for Detection of *Trichomonas vaginalis* with Prospectively Collected Specimens from Men and Women.** *J Clin Microbiol*. 2018; 56(2): pii: e01091-17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 44. Nye MB, Schwabke JR, Body BA: **Comparison of APTIMA *Trichomonas vaginalis* transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women.** *Am J Obstet Gynecol*. 2009; 200(2): 188.e1–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 45. Badman SG, Vallely LM, Toliman P, *et al.*: **A novel point-of-care testing strategy for sexually transmitted infections among pregnant women in high-burden settings: results of a feasibility study in Papua New Guinea.** *BMC Infect Dis*. 2016; 16: 250.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 46. Ridzon R, Farley T, Dolinger DL: **Point of Care Tests for Diagnosis of Sexually Transmitted Infections: A Landscape Analysis.** *J HIV AIDS*. 2016; 2.
[Publisher Full Text](#)
 47. **F** Gaydos CA, Schwabke J, Dombrowski J, *et al.*: **Clinical performance of the Solana® Point-of-Care *Trichomonas* Assay from clinician-collected vaginal swabs and urine specimens from symptomatic and asymptomatic women.** *Expert Rev Mol Diagn*. 2017; 17(3): 303–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 48. Gaydos CA, Hobbs M, Marrazzo J, *et al.*: **Rapid Diagnosis of *Trichomonas vaginalis* by Testing Vaginal Swabs in an Isothermal Helicase-Dependent AmpliVue Assay.** *Sex Transm Dis*. 2016; 43(6): 369–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 49. Hegazy MM, El-Tantawy NL, Soliman MM, *et al.*: **Performance of rapid immunochromatographic assay in the diagnosis of *Trichomoniasis vaginalis*.** *Diagn Microbiol Infect Dis*. 2012; 74(1): 49–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
 50. Nathan B, Appiah J, Saunders P, *et al.*: **Microscopy outperformed in a comparison of five methods for detecting *Trichomonas vaginalis* in symptomatic women.** *Int J STD AIDS*. 2015; 26(4): 251–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 51. Sheele JM, Crandall CJ, Arko BL, *et al.*: **The OSOM® *Trichomonas* Test is unable to accurately diagnose *Trichomonas vaginalis* from urine in men.** *Am J Emerg Med*. 2019; 37(5): 1002–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
 52. **F** Garrett NJ, Osman F, Maharaj B, *et al.*: **Beyond syndromic management: Opportunities for diagnosis-based treatment of sexually transmitted infections in low- and middle-income countries.** *PLoS One*. 2018; 13(4): e0196209.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 53. Csonka GW: **Trichomonal vaginitis treated with one dose of metronidazole.** *Br J Vener Dis*. 1971; 47(6): 456–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 54. Woodcock KR: **Treatment of trichomonal vaginitis with a single oral dose of metronidazole.** *Br J Vener Dis*. 1972; 48(1): 65–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 55. Thin RN, Symonds MA, Booker R, *et al.*: **Double-blind comparison of a single dose and a five-day course of metronidazole in the treatment of trichomoniasis.** *Br J Vener Dis*. 1979; 55(5): 354–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 56. Aubert JM, Sesta HJ: **Treatment of vaginal trichomoniasis. Single, 2-gram dose of metronidazole as compared with a seven-day course.** *J Reprod Med*. 1982; 27(12): 743–5.
[PubMed Abstract](#)
 57. **F** Howe K, Kissinger PJ: **Single-Dose Compared With Multidose Metronidazole for the Treatment of Trichomoniasis in Women: A Meta-Analysis.** *Sex Transm Dis*. 2017; 44(1): 29–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 58. Kissinger P, Mena L, Levison J, *et al.*: **A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of *Trichomonas vaginalis* among HIV-infected women.** *J Acquir Immune Defic Syndr*. 2010; 55(5): 565–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 59. Kissinger P, Muzny CA, Mena LA, *et al.*: **Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial.** *Lancet Infect Dis*. 2018; 18(11): 1251–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 60. Muzny CA, Richter S, Kissinger P: **Is It Time to Stop Using Single-dose Oral Metronidazole for the Treatment of Trichomoniasis in Women?** *Sex Transm Dis*. 2019; 46(5): e57–e59.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 61. Sheehy O, Santos F, Ferreira E, *et al.*: **The use of metronidazole during pregnancy: A review of evidence.** *Curr Drug Saf*. 2015; 10(2): 170–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 62. Latif AS, Mason PR, Marowa E: **Urethral trichomoniasis in men.** *Sex Transm Dis*. 1987; 14(1): 9–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
 63. Khrianin AA, Reshetnikov OV: **[Clinical and microbiological efficacy of metronidazole and ornidazole in the treatment of urogenital trichomoniasis in men].** *Antibiot Khimioter*. 2006; 51(1): 18–21.
[PubMed Abstract](#)
 64. Viitanen J, Haataja H, Männistö PT: **Concentrations of metronidazole and tinidazole in male genital tissues.** *Antimicrob Agents Chemother*. 1985; 28(6): 812–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 65. Videau D, Niel G, Siboulet A, *et al.*: **Secnidazole. A 5-nitroimidazole derivative with a long half-life.** *Br J Vener Dis*. 1978; 54(2): 77–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 66. Hillström L, Pettersson L, Pålsson E, *et al.*: **Comparison of ornidazole and tinidazole in single-dose treatment of trichomoniasis in women.** *Br J Vener Dis*. 1977; 53(3): 193–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 67. Sobel JD, Nyirjesy P, Brown W: **Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis.** *Clin Infect Dis*. 2001; 33(8): 1341–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Henien M, Nyirjesy P, Smith K: **Metronidazole-Resistant Trichomoniasis: Beneficial Pharmacodynamic Relationship With High-Dose Oral Tinidazole and Vaginal Paromomycin Combination Therapy.** *Sex Transm Dis*. 2019; 46(1): e1–e2.
[PubMed Abstract](#) | [Publisher Full Text](#)
 69. Nyirjesy P, Gilbert J, Mulcahy LJ: **Resistant trichomoniasis: successful treatment with combination therapy.** *Sex Transm Dis*. 2011; 38(10): 962–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
 70. Davidson RN, den Boer M, Ritmeijer K: **Paromomycin.** *Trans R Soc Trop Med Hyg*. 2009; 103(7): 653–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
 71. Nyirjesy P, Sobel JD, Weitz MV, *et al.*: **Difficult-to-treat trichomoniasis: results with paromomycin cream.** *Clin Infect Dis*. 1998; 26(4): 986–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 72. Pearlman MD, Yashar C, Ernst S, *et al.*: **An incremental dosing protocol for women with severe vaginal trichomoniasis and adverse reaction to metronidazole.** *Am J Obstet Gynecol*. 1996; 174(3): 934–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 73. Gendelman SR, Pien LC, Gutta RC, *et al.*: **Modified oral metronidazole desensitization protocol.** *Allergy Rhinol (Providence)*. 2014; 5(2): 66–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 74. Muzny CA, Schwabke JR: **The clinical spectrum of *Trichomonas vaginalis* infection and challenges to management.** *Sex Transm Infect*. 2013; 89(6): 423–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 75. Muzny C, Barnes A, Mena L: **Symptomatic *Trichomonas vaginalis* infection in the setting of severe nitroimidazole allergy: successful treatment with boric acid.** *Sex Health*. 2012; 9(4): 389–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
 76. Backus KV, Muzny CA, Beauchamps LS: ***Trichomonas vaginalis* Treated With Boric Acid in a Metronidazole Allergic Female.** *Sex Transm Dis*. 2017; 44(2): 120.
[PubMed Abstract](#) | [Publisher Full Text](#)
 77. Kissinger P: **Should expedited partner treatment for women with *Trichomonas vaginalis* be recommended?** *Sex Transm Dis*. 2010; 37(6): 397–8.
[PubMed Abstract](#)
 78. Schillinger JA, Gorwitz R, Rietmeijer C, *et al.*: **The Expedited Partner Therapy Continuum: A Conceptual Framework to Guide Programmatic Efforts to Increase Partner Treatment.** *Sex Transm Dis*. 2016; 43(2 Suppl 1): S63–75.
[PubMed Abstract](#) | [Publisher Full Text](#)

79. Golden MR, Whittington WL, Handsfield HH, *et al.*: **Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection.** *N Engl J Med.* 2005; **352**(7): 676–85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
80. Kissinger P, Schmidt N, Mohammed H, *et al.*: **Patient-delivered partner treatment for *Trichomonas vaginalis* infection: a randomized controlled trial.** *Sex Transm Dis.* 2006; **33**(7): 445–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
81. Schwebke JR, Desmond RA: **A randomized controlled trial of partner notification methods for prevention of trichomoniasis in women.** *Sex Transm Dis.* 2010; **37**(6): 392–6.
[PubMed Abstract](#)
82. Gannon-Loew KE, Holland-Hall C, Bonny AE: **A Review of Expedited Partner Therapy for the Management of Sexually Transmitted Infections in Adolescents.** *J Pediatr Adolesc Gynecol.* 2017; **30**(3): 341–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Paul Nyirjesy**

Department of Obstetrics and Gynecology, Drexel University College of Medicine, Philadelphia, PA, USA

Competing Interests: No competing interests were disclosed.

2. **Jack Sobel**

Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI, USA

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research